ChronoScale (CHRN) Registration filing summary
Event summary combining transcript, slides, and related documents.
Registration filing summary
6 Oct, 2026Company overview and business model
Cloud services operate through a wholly owned subsidiary at third-party colocation centers in Colorado, Minnesota and Utah; AI/ML developers pay fixed rates for energized space supported by provided equipment.
After the May 5, 2026 business combination, operations included cloud and legacy exoskeleton businesses; a July 1 holding-company restructuring established the public parent, and the legacy business was divested on September 30, 2026.
On May 29, 2026, the Board committed to focus solely on the Cloud Business; the plan was announced June 4, 2026, and the divestiture closed September 30, 2026.
Use of proceeds and capital allocation
Unless an offering supplement specifies otherwise, net proceeds are expected to fund working capital and general corporate purposes; management has broad discretion over allocation and timing.
Risk factors and disclosures
Key risks include access to timely, acceptable financing; debt and equity market conditions; customer concentration and renewals; personnel retention; changing capital plans; higher costs and unexpected capex.
Other cited risks include competition and economic conditions, internal-control effectiveness, litigation concerning the business combination, cash flow and capital access, market conditions, and realizing benefits from the Cloud Business focus.
The planned Microsoft deployment depends on favorable financing and customary development, construction and operating conditions and milestones; missed milestones may trigger penalties or credits for the counterparty.
Junior subordinated debt would rank behind senior indebtedness and be structurally subordinated to subsidiary liabilities and preferred equity; holding-company payments depend on subsidiary distributions and available cash.
Latest events from ChronoScale
- Seven directors remain on the ballot; Davis and Jones receive disposition-related separation benefits.CHRN
Proxy filing - Revenue rose 148% as major AI deployments target $1B annualized run-rate.CHRN
Q3 2026 - Revenue fell 29% to $12.8M, net loss reached $11.7M, and a major business combination is pending.CHRN
Q4 2025 - Record Q4 revenue, improved margins, and narrowed net loss highlight strong operational progress.CHRN
Q4 2024 - Revenue fell 10% year-over-year, margins improved, but liquidity risks and funding needs remain.CHRN
Q1 2025 - Q2 revenue up 5%, margins improved, but going concern risk remains without new funding.CHRN
Q2 2024 - Q3 revenue dropped 10% YoY, net loss narrowed, and CMS reimbursement was achieved.CHRN
Q3 2024 - Q2 2025 revenue dropped 58% to $2.1M as Enterprise Health sales lagged, but Personal Health surged.CHRN
Q2 2025 - Q3 2025 revenue rose 2% YoY, gross margin hit 60.3%, and liquidity risks persist.CHRN
Q3 2025